The NAD+-consuming enzyme CD38 is elevated in individuals predisposed to Alzheimer’s, and blocking it improves the metabolic health and cognition of mice that model Alzheimer’s. 


Principal investigator Michal Shwartz, PhD (Image: Jonathan Bloom).

Brain &amp; Neurons

Aside from diet and exercise, senolytics — compounds that remove age-promoting cells — may rejuvenate the immune system and reduce the risk of neurodegeneration and dementia. 

<p>Model: 5xFAD Alzheimer&#8217;s model mice</p>
<p>Dosage (oral): 20 mg/kg VBIT-4</p>


Cognitive deficits, neurodegeneration, and neuroinflammation are prevented in an Alzheimer’s mouse model with a new drug that targets VDAC1 — a protein that transports molecules like NAD+ to and from mitochondria. 


Principal Investigator Dr. Varda Shoshan-Barmatz | NIBN 

Explore the findings of a groundbreaking study conducted by Israeli scientists, revealing the potential of manipulating an NAD-linked protein in curbing Alzheimer's disease symptoms. Discover the promising advancements in Alzheimer's research and the role of NAD in combating this neurodegenerative condition. Read more on NAD.

Search Result: Israeli scientists

Blocking NAD+ Breakdown Improves Brain Fitness and Cognition, New Study Shows

Scientists Reveal How to Slow Brain Aging with Senolytics

Israeli Scientists Find Potential Breakthrough Drug for Alzheimer’s